These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 17627612

  • 1. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
    Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, Nishio K.
    Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W, Petricoin EF, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.
    Breast Cancer Res; 2013 Sep; 15(5):R85. PubMed ID: 24044505
    [Abstract] [Full Text] [Related]

  • 5. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
    Diermeier-Daucher S, Breindl S, Buchholz S, Ortmann O, Brockhoff G.
    Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, Averbuch S, Baselga J.
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [Abstract] [Full Text] [Related]

  • 8. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
    Shi X, Xu L, Yu J, Fang X.
    Exp Cell Res; 2009 Oct 01; 315(16):2847-55. PubMed ID: 19497323
    [Abstract] [Full Text] [Related]

  • 9. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA, Steins A, Fessler E, Stathi P, Lesterhuis WJ, Krishnadath KK, Vermeulen L, Medema JP, Bijlsma MF, van Laarhoven HWM.
    Gastroenterology; 2017 Jul 01; 153(1):63-76.e14. PubMed ID: 28286209
    [Abstract] [Full Text] [Related]

  • 10. HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).
    Sollome JJ, Thavathiru E, Camenisch TD, Vaillancourt RR.
    Cell Signal; 2014 Jan 01; 26(1):70-82. PubMed ID: 24036211
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM.
    Cancer Res; 2008 Jul 15; 68(14):5878-87. PubMed ID: 18632642
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
    Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M.
    Cancer Res; 2009 Dec 15; 69(24):9330-6. PubMed ID: 19934333
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Re-epithelialization from human skin explant cultures is promoted by ligand-activated HER3 receptor.
    Forsberg S, Rollman O.
    J Dermatol Sci; 2010 Jul 15; 59(1):7-15. PubMed ID: 20537867
    [Abstract] [Full Text] [Related]

  • 19. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.
    Nagumo Y, Faratian D, Mullen P, Harrison DJ, Hasmann M, Langdon SP.
    Mol Cancer Res; 2009 Sep 15; 7(9):1563-71. PubMed ID: 19737968
    [Abstract] [Full Text] [Related]

  • 20. Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism.
    Lee L, Ramos-Alvarez I, Moody TW, Mantey SA, Jensen RT.
    Biochim Biophys Acta Mol Cell Res; 2020 Apr 15; 1867(4):118625. PubMed ID: 31862538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.